Detalhe da pesquisa
1.
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Future Oncol
; 17(16): 1987-2003, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33682447